SCHEMBL2593036

SCHEMBL2593036

COCC(C)(C)COc1c(-c2ccc3c(c2)COC3=O)ccc(OC(F)F)c1OC

nearest known ligand 0.41

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
PRF1 P14222 8/20 0.41
PDE4D Q08499 9/20 0.37
CYP3A4 P08684 1/20 0.36
ACHE P22303 1/20 0.35
NR3C1 P04150 1/20 0.34
PGR P06401 1/20 0.34
PDE4A P27815 1/20 0.34
PDE4B Q07343 1/20 0.34
PDE4C Q08493 1/20 0.34
MAOA P21397 1/20 0.34
MAOB P27338 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2588996 0.92 PRF1 (0.41) PRF1PDE4DACHENR3C1PGR
SCHEMBL2592364 0.90 PRF1 (0.46) PRF1PDE4DCYP3A4ACHE
SCHEMBL2593350 0.88 PRF1 (0.43) PRF1PDE4DCYP3A4PDE4APDE4B
SCHEMBL2584975 0.86 PRF1 (0.43) PRF1PDE4DCYP3A4PDE4APDE4B
SCHEMBL2583954 0.85 PRF1 (0.42) PRF1PDE4DCYP3A4PDE4APDE4B
SCHEMBL2588180 0.85 PDE4D (0.43) PRF1PDE4DCYP3A4PDE4APDE4B
SCHEMBL2591538 0.82 PRF1 (0.38) PRF1PDE4DCYP3A4PDE4APDE4B
SCHEMBL2592870 0.82 PRF1 (0.45) PRF1PDE4DCYP3A4ACHEPDE4A
SCHEMBL2589787 0.81 PRF1 (0.48) PRF1PDE4DCYP3A4ACHE
SCHEMBL7706052 0.81 PRF1 (0.39) PRF1PDE4DCYP3A4PDE4APDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2563770-B1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA AS (DK) 2016-03-23 EP claimed
US-9051290-B2 Biaryl phosphodiesterase inhibitors LEO PHARMA A/S (DK) 2015-06-09 US claimed
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2013-03-07 US claimed
EP-2563770-A1 BIARYL PHOSPHODIESTERASE INHIBITORS Leo Pharma A/S (DK) 2013-03-06 EP claimed
WO-2011134468-A1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2011-11-03 WO claimed
EP-2563770-B1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA AS (DK) 2016-03-23 EP disclosed
US-9051290-B2 Biaryl phosphodiesterase inhibitors LEO PHARMA A/S (DK) 2015-06-09 US disclosed
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2013-03-07 US disclosed
EP-2563770-A1 BIARYL PHOSPHODIESTERASE INHIBITORS Leo Pharma A/S (DK) 2013-03-06 EP disclosed
WO-2011134468-A1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2011-11-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS PDE3B, PDE3A, PDE4A PRF1 3550/4885PDE4D 10/4885CYP3A4 324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.